Earlier, CiMaas had filed for bankruptcy, effective June 11, 2024, due to financial challenges that hindered its ability to fund necessary clinical studies, despite having proprietary feeder cell technology and advanced NK cell expansion methodology.
Thanks to an investment from 819 Evergreen Fund I, we are pleased to be able to continue working on our ambitions: cure cancer patients by making Natural Killer cells a reality. Our activities will be realised in Maastricht.
CiMaas is focused on transforming cancer treatment with immunotherapies. These therapies aim to harness the body's immune system to treat metastatic and late-stage cancers, addressing unmet needs in areas where current treatments are often ineffective, especially in advanced cases.
The company is also working towards having clinical-grade NK cell production ready, with plans to initiate clinical research in collaboration with various partners, aiming for robust and lasting solutions for patients with limited treatment options.
Collection
[
|
...
]